

CLAIMS:

1. A peptidic compound having the formula (I):

5 Tza-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-Lys-Gln-X14-Glu-Ser-Arg-
 Arg-Ala-Gln-X21-Phe-Ile-Glu-Trp-Leu-Leu-Ala-X29-Gly-Pro-Glu-Ser-Gly-
 Ala-Pro-Pro-Pro-Ser-R¹

(I)

10 X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile, Phe,
 Phenylglycine, 1-Naphthylalanine, 2-Fluorophenylalanine,
 Cyclohexylglycine and tert-Leucine,

 X14 represents an amino acid residue selected from Leu and Nle

 X21 represents an amino acid residue selected from Asp and Glu,

15 X29 represents an amino acid residue selected from Gly and Thr,

 R¹ represents OH or NH₂

or a salt or solvate thereof.

20 2. A compound of claim 1, wherein
 the C-terminal group R¹ is OH.

3. A compound according to any one of claims 1 - 2, wherein,

 X10 represents Leu,

25 X14 represents an amino acid residue selected from Leu and Nle

 X21 represents an amino acid residue selected from Asp and Glu,

 X29 represents an amino acid residue selected from Gly and Thr,

 R¹ represents OH,

or a salt or solvate thereof.

30

4. A compound according to any one of claims 1 - 3, wherein,

X10 represents Tyr,

X14 represents an amino acid residue selected from Leu and Nle,

X21 represents Glu,

X29 represents an amino acid residue selected from Gly and Thr,

5 R¹ represents OH,

or a salt or solvate thereof.

5. A compound according to any one of claims 1 - 4, wherein,

X10 represents 1-Naphthylalanine,

10 X14 represents an amino acid residue selected from Leu and Nle,

X21 represents an amino acid residue selected from Asp and Glu,

X29 represents Thr,

R¹ represents OH,

or a salt or solvate thereof.

15

6. A compound according to any one of claims 1 - 5, wherein,

X10 represents Cyclohexylglycine,

X14 represents an amino acid residue selected from Leu and Nle,

X21 represents an amino acid residue selected from Asp and Glu,

20 X29 represents Thr,

R¹ represents OH,

or a salt or solvate thereof.

7. A compound according to any one of claims 1 - 6, wherein,

25 X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile,
Phenylglycine, 1-Naphthylalanine, 2-Fluorophenylalanine and
Cyclohexylglycine,

X14 represents Leu,

X21 represents an amino acid residue selected from Asp and Glu,

30 X29 represents an amino acid residue selected from Gly and Thr,

R¹ represents OH,

or a salt or solvate thereof.

8. A compound according to any one of claims 1 - 7, wherein,

X10 represents an amino acid residue selected from Tyr, Leu, Ile, Phe, 1-Naphthylalanine, Cyclohexylglycine and tert-Leucine

X14 represents Nle,

X21 represents an amino acid residue selected from Asp and Glu,

X29 represents Thr,

R¹ represents OH,

or a salt or solvate thereof.

9. A compound according to any one of claims 1 - 8, wherein,

X10 represents an amino acid residue selected from Leu, Phe, 1-Naphthylalanine, 2-Fluorophenylalanine and Cyclohexylglycine,

X14 represents an amino acid residue selected from Leu and Nle

X21 represents Asp,

X29 represents Thr,

R¹ represents OH,

or a salt or solvate thereof.

10. A compound according to any one of claims 1 - 9, wherein,

X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile, Phenylglycine, 1-Naphthylalanine, Cyclohexylglycine and tert-Leucine,

X14 represents an amino acid residue selected from Leu and Nle

X21 represents Glu,

X29 represents an amino acid residue selected from Gly and Thr,

R¹ represents OH,

or a salt or solvate thereof.

11. A compound according to any one of claims 1 - 10, wherein,

X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile, Phe, Phenylglycine, 1-Naphthylalanine, 2-Fluorophenylalanine, Cyclohexylglycine and tert-Leucine,

X14 represents an amino acid residue selected from Leu and Nle

5 X21 represents an amino acid residue selected from Asp and Glu,

X29 represents Thr,

R¹ represents OH,

or a salt or solvate thereof.

10 12. A compound according to any one of claims 1 - 11, wherein,

X10 represents an amino acid residue selected from Tyr, Leu and Val,

X14 represents Leu

X21 represents Glu,

X29 represents Gly,

15 R¹ represents OH,

or a salt or solvate thereof.

13. A compound according to any one of claims 1 - 12, selected from the compounds of SEQ ID NO: 3 - 25 as well as salts or solvates thereof.

20

14. A compound according to any one of claims 1 - 13, selected from the compounds of SEQ ID NO: 3, 5, 6, 9, 15, 20, 23, 24, and 25 as well as salts or solvates thereof.

25 15. A compound of any one of claims 1 - 14 for use in medicine, particularly in human medicine.

16. The compound for use according to claim 15 which is present as an active agent in a pharmaceutical composition together with at least one
30 pharmaceutically acceptable carrier.

17. The compound for use according to claim 15 or 16 together with at least one additional therapeutically active agent, wherein the additional therapeutically active agent is selected from the series of Insulin and Insulin derivatives, GLP-1, GLP-1 analogues and GLP-1 receptor agonists dual GLP1/glucagon receptor agonists, dual GLP1/GIP receptor agonists, PYY3-36 or analogues thereof, pancreatic polypeptide or analogues thereof, Glucagon receptor agonists, GIP receptor agonists or antagonists, ghrelin antagonists or inverse agonists, Xenin and analogues thereof, DDP4 inhibitors, SGLT2 inhibitors, Biguanides Thiazolidinediones, dual PPAR agonists, Sulfonylureas, Meglitinides, alpha-glucosidase inhibitors, Amylin and Amylin analogues, GPR119 agonists Cycloset, inhibitors of 11-beta-HSD, activators of glucokinase, inhibitors of DGAT, inhibitors of protein tyrosine phosphatase 1, inhibitors of glucose-6-phosphatase, inhibitors of fructose-1,6-bisphosphatase, inhibitors of glycogen phosphorylase, inhibitors of phosphoenol pyruvate carboxykinase, inhibitors of glycogen synthase kinase, inhibitors of pyruvate dehydrogenase kinase, alpha2-antagonists, CCR-2 antagonists HMG-CoA-reductase inhibitors, fibrates, nicotinic acid and the derivatives thereof, PPAR-(alpha, gamma or alpha/gamma) agonists or modulators, PPAR-delta agonists, ACAT inhibitors, cholesterol absorption inhibitors, bile acid-binding substances, IBAT inhibitors, MTP inhibitors, modulators of PCSK9, HDL-raising compounds, ABC regulators, active substances for the treatment of obesity, such as Sibutramine, Tesofensine, Orlistat, CB-1 receptor antagonists, MCH-1 antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists, NPY4 agonists, beta-3-agonists, leptin or leptin mimetics, agonists of the 5HT_{2c} receptor, or the combinations of bupropione/naltrexone (CONTRAVE), bupropione/zonisamide (EMPATIC), bupropione/phentermine or pramlintide/metreleptin, drugs for influencing high blood pressure, chronic heart failure or atherosclerosis, such as angiotensin II receptor antagonists, ACE inhibitors, ECE inhibitors, diuretics, beta-blockers, calcium

antagonists, centrally acting hypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors.

- 5 18. The compound for use according to any one of claims 15 - 17 for treating hypoglycemia, increase blood glucose levels, or as adjunctive therapy with insulin.
- 10 19. The compound for use according to any one of claims 15 - 17 for reducing and maintaining body weight, as antidote for beta-blockers and calcium-channel blockers toxication and for inducing temporary relaxation of the gastro-intestinal system for radiological uses.
- 15 20. The compound for use according to any one of claims 15 - 17 for the treatment or prevention of hypoglycemia, type 2 diabetes mellitus and for delaying progression from prediabetes to type 2 diabetes.
- 20 21. A pharmaceutical composition comprising at least one compound according to any one of claims 1 – 14 or a physiologically acceptable salt or solvents of any of them.
- 25 22. Use of at least one compound of formula I according to any one of claims 1 – 14 in the manufacture of a medicament for treating hypoglycemia.
- 30 23. Use of at least one compound of formula I according to any one of claims 1 – 14 and of at least one other compound in the manufacture of a medicament for treating hypoglycemia.
24. The use according to claims 22 – 23 wherein the medicament is to be administered simultaneously, separately or sequentially.

25. The use according to claims 22 – 24 wherein the medicament is to be administered parenterally.